OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Taylor on Assessing ChatGPT's Ability to Offer Specific Information in Hematologic Malignancies

November 19th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

November 18th 2025

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Dr Masserelli on the Clinical Presentation and Management of LEMS in SCLC

November 18th 2025

Erminia Massarelli, MD, PhD, MS, discusses the clinical presentation and management of Lambert–Eaton myasthenic syndrome in the context of small cell lung cancer.

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18th 2025

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

Dr Raab on Patient Enrollment and the Design of the MajesTEC-5 Trial in NDMM

November 18th 2025

Marc S. Raab, MD, details the patient characteristics and design of the phase 2 MajesTEC-5 trial evaluating teclistamab in newly diagnosed multiple myeloma.

Dr Marron on the Evolving Role of Tarlatamab in SCLC

November 15th 2025

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

Dr Bhora on How Perioperative Immunotherapy Is Reshaping the Treatment Paradigm in Resectable NSCLC

November 15th 2025

Faiz Bhora, MD, FACS, discusses how data from the CheckMate 816, KEYNOTE-091, and AEGEAN trial have transformed perioperative therapy in resectable NSCLC.

Dr Desai on the Treatment Landscape of Polycythemia Vera

November 14th 2025

Ruchi J. Desai, MD, discusses the treatment landscape of polycythemia vera and unmet needs in the space.

Dr Saad on the Rationale for AI-Generated Synthetic Cohorts in Metastatic Breast Cancer Research

November 14th 2025

Eddy Saad, MD, discusses how AI-generated synthetic cohorts derived from real-world data may accelerate trial design and collaboration in metastatic breast cancer.

Dr Jakubowiak on How the PERSEUS Study Informed the ATLAS Trial in Multiple Myeloma

November 13th 2025

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

Dr Randall on the Need for Precision Survivorship Care in Pediatric and AYA Sarcoma

November 13th 2025

R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.

Dr Yuan on the Evolving Landscape of ADCs in HER2+ Breast Cancer

November 13th 2025

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.

Dr Visco on Ongoing Research to Optimize Upfront MCL Therapy

November 13th 2025

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Dr Tagawa on the Safety Profile of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 12th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the safety profile of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Orloff on OS Outcomes With Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

November 12th 2025

Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.

Dr Liu on the Efficacy of Zidesamtinib in ROS1 Fusion+ NSCLC

November 12th 2025

Stephen Liu, MD, discussed efficacy data with zidesamtinib in ROS1 fusion–positive non-small cell lung cancer that were reported in the ARROS-1 trial.

Dr Camidge on the Efficacy and Safety of Neladalkib in ALK+ Solid Tumors

November 12th 2025

D. Ross Camidge, MD, PhD, discusses safety and efficacy data seen with neladalkib in TKI-naive and -pretreated patients with ALK-positive solid tumors.

Dr Bellmunt on the Design of the IMvigor011 Trial of ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 12th 2025

Joaquim Bellmunt, MD, PhD, discusses the phase 3 IMvigor011 trial of ctDNA-guided adjuvant atezolizumab in MIBC.

Dr George on the Role of Radioligand Therapy in Prostate Cancer Management

November 12th 2025

Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.

Dr Raab on the Rationale for Adding Teclistamab to Daratumumab-Based Induction in NDMM

November 12th 2025

Marc S. Raab, MD, discusses the rationale for assessing teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.